It was concluded that E1231 ameliorated HFHC-induced NAFLD development by increasing the activities of SIRT1 and p-AMPKα and decreasing the key lipogenesis-related proteins, including SREBP-1c, ACC, SCD-1, and PPARγ2. This evidence concerns the gene SREBF1 and metabolic dysfunction-associated steatotic liver disease.